The Exelon Patch (Transdermal Rivastigmine) for the treatment of severe delirium in elderly subacute care inpatients

Phase 3

• Conditions: Delirium in elderly subacute care inpatients; Neurological - Other neurological disorders

• Registration Number: ACTRN12609001020279
• Lead Sponsor: Melbourne Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-11-24
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Severe Delirium (Confusion assessment method positive, delirium rating scale 12 or more)

Exclusion Criteria

Informed consent unable to be obtained
Deficits in cardiac conducting system, resting pulse <50, intolerance or allergy to rivastigmine, carbamates or excipients.
Severe dysphasia, visual or hearing impairment, or non english speaking such that unable to complete scales.
Expected prognosis or discharge less than 2 weeks.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Peak Delirium Severity on Delirium Rating Scale.[week two of treatment]

Secondary Outcome Measures

Name	Time	Method
nil[nil]